Amgen Stock Holdings Lifted by Capital Research Global Investors

Capital Research Global Investors boosts stake in Amgen by 2.7% in Q3

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Capital Research Global Investors, a major institutional investor, increased its stake in Amgen Inc. (NASDAQ:AMGN) by 2.7% in the third quarter, according to a recent filing with the Securities and Exchange Commission. The firm now owns 4,731,290 shares of the medical research company's stock, representing about 0.88% of Amgen's total shares outstanding.

Why it matters

Amgen is a leading biotechnology company focused on developing innovative human therapeutics to address serious illnesses. Changes in major institutional investors' holdings can signal shifts in market sentiment and influence the stock price performance.

The details

According to the filing, Capital Research Global Investors purchased an additional 122,631 shares of Amgen during the third quarter, bringing its total position to 4,731,290 shares. This represents about 0.88% of Amgen's total outstanding shares. Capital Research Global Investors is a prominent institutional investor that manages a diverse portfolio of investments across various sectors.

  • Capital Research Global Investors increased its Amgen stake in the third quarter of 2026.

The players

Capital Research Global Investors

A major institutional investor that manages a diverse portfolio of investments across various sectors.

Amgen Inc.

A global biotechnology company focused on discovering, developing, manufacturing, and delivering human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

The increase in Capital Research Global Investors' stake in Amgen suggests the institutional investor sees continued growth potential in the biotechnology company's business and pipeline. This could signal broader market confidence in Amgen's ability to deliver value for shareholders.